

83900-S2

NDA 83-900/S-002

Smith Kline & French Laboratories
Attention: J.F. Cassin
1500 Spring Garden Street
P.O. Box 7929
Philadelphia, PA 19101

Gentlemen:

We acknowledge receipt on April 12, 1977, of your communication of April 12, 1977. This is regarded as a supplemental new drug application submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act for Amphetamine Sulfate Tablets, 5 mg.

The supplemental application provides for revised container labels.

We have completed the review of this supplemental application and it is approved. Our letter of February 26, 1976, detailed the conditions relating to the approval of this application.

The material submitted is being retained in our files.

Sincerely yours,

/S/

Maryin Seife, M.D.

Director

Division of Generic Drug Monographs

Office of Drug Monographs

Bureau of Drugs

cc:

PHI Do

Dup

HFD-614 HFD-616

JVVkarusaitis/JMyer/Marski

r/d/ init. JMeyer/MSeife 5-9-77

f/t/wlb/5-9-77

approved.

Handwritten: 5/9/77

Handwritten: JMeyer 5/10/77

Handwritten: 5/14/77

NOTICE OF APPROVAL NEW DRUG APPLICATION OR SUPPLEMENT		NDA NUMBER <div style="text-align: right; margin-right: 20px;">0116</div> 83-900
		DATE APPROVAL LETTER ISSUED
TO: Press Relations Staff (HFI-40)	FROM: <input checked="" type="checkbox"/> Bureau of Drugs XXXX <input type="checkbox"/> Bureau of Veterinary Medicine	
ATTENTION Forward original of this form for publication only after approval letter has been issued and the date of approval has been entered above.		
<div style="border: 1px solid black; padding: 5px; font-weight: bold; font-size: 1.2em;">APPROVED</div>		
TYPE OF APPLICATION		
<input type="checkbox"/> ORIGINAL NDA <input type="checkbox"/> SUPPLEMENT TO NDA <input type="checkbox"/> REVISION TO NDA <input type="checkbox"/> REVISION TO NDA		
CATEGORY <input type="checkbox"/> HUMAN <input type="checkbox"/> VETERINARY		
TRADE NAME (or other designated name) AND ESTABLISHED OR NONPROPRIETARY NAME (if any) OF DRUG		
amphetamine sulfate		
DOSAGE FORM		HOW DISPENSED
tablet		<input type="checkbox"/> RX <input checked="" type="checkbox"/> OTC
ACTIVE INGREDIENT(S) (as declared on label. List by established or nonproprietary name(s) and include amount(s), if amount is declared on label.)		
amphetamine sulfate 5 mg.		
NAME OF APPLICANT (Include City and State)		
Smith Kline & French Laboratories Philadelphia, PA 19101		
PRINCIPAL INDICATION OR PHARMACOLOGICAL CATEGORY		
amphetamine		
COMPLETE FOR VETERINARY ONLY		
ANIMAL SPECIES FOR WHICH APPROVED		
COMPLETE FOR SUPPLEMENT ONLY		
CHANGE APPROVED TO PROVIDE FOR		
labeling revision		
FORM PREPARED BY		
NAME majarski	DATE	
FORM APPROVED BY		
NAME jlmeyer	DATE	

Name and Address of Applicant (City and State) Smith Kline & French Laboratories Philadelphia, PA 19101		Original _____ Amendment _____ Supplement <input checked="" type="checkbox"/> xxxxxx Resubmission _____ Correspondance _____ Report _____ Other _____
Purpose of Amendment/Supplement revised container labels - expiration dating added		Date(s) of Submission(s) 4-12-77
Pharmacological Category amphetamine	Name Of Drug amphetamine sulfate	How Dispensed <input checked="" type="checkbox"/> Rx <input type="checkbox"/> xxxxx <input type="checkbox"/> OTC <input type="checkbox"/>
Dosage Form(s) tablet	Potency 5 mg.	
Environmental Impact Analysis Report	Samples	Related IND/NDA/MF(s)

Labeling

see medical officer's review of 5-4-77

Biologic Availability

Establishment Inspection

Components, Composition, Manufacturing and Controls

Remarks

approval majarski

Conclusion

Reviewer:

Date:

1/5/

5/9/77

REVIEW OF SUPPLEMENT

DATE COMPLETED: 5-4-77

ANDA #: 83-900/S-002

CO. NAME: Smith Kline & French
Philadelphia, PA 19101

APPROVAL DATE: 2-26-76

NAME OF DRUG: Benzedrine Tablets 5 mg., 10 mg.
(Amphetamine sulfate 5 mg)

DATE OF SUBMISSION: 4-12-77

TYPE OF SUBMISSION: Supplement - labeling revision
Immediate container label revised.

CLINICAL EVALUATION:


1. Review of Labeling:

- a) Container labels: Satisfactory
5 mg., bottles of 100
will use "expiration" date in May 1977
- b) Insert labeling: not submitted

CONCLUSIONS: Container labeling is satisfactory for the safe and effective use of this product.

RECOMMENDATIONS: Approve supplement S-002.

cc:dup
VVK/wlb/5-5-77


V.V. Karusaitis, M.D.

SMITH KLINE & FRENCH LABORATORIES

1500 Spring Garden St., P.O. Box 7929, Philadelphia, PA 19101 • 215-854-4000

cable SMITHKLINE PHILADELPHIA
telex 83-4487

NDA 83-900

April 12, 1977

'Benzedrine' Tablets

Division of Generic Drug Products
Office of Drug Monographs
Bureau of Drugs HFD #530
Attn: Document Control Room 16-72
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

NDA NO. 83-900 S/002
NDA SUPPL FOR Labeling Revision

Gentlemen:

FPL

In accordance with § 314.8 (a)(5)(ix), I am enclosing 12 final printed copies of immediate container labels for 'Benzedrine' (brand of amphetamine sulfate) Tablets, 5 mg. (100's - Code AG) revised to add the word "Expires". No expiration date has been used previously for the 5 mg. strength of this product. This label will be placed in use in May.

Code AG also differs from prior labeling in that the NDC number has been changed from alpha-numeric to all numeric to facilitate adaptation into computerized drug programs.

Similar label changes were submitted for the 10 mg. strength product October 15, 1975.


Stability data was incorporated in the Facilities and Controls Section 8, pages 11 and 12, of our original submission dated August 6, 1971 and later updated in our communication dated October 15, 1975 to substantiate a 5 year expiration date for both strengths of this product.

Sincerely,

J. F. Cassin

J. F. Cassin
Manager, Regulatory Affairs

att.
jm



Labeling: ORIG
NDA No: 83-900 Rec'd. 4-12-77
Reviewed by: McJunk 5/9/77

NDA 83-900

'BENZEDRINE' TABLETS

5 mg. - 100's

APPROVED MAY 11 1977 *MS* 100 tablets 5 mg.
NDC 0007-3191-20

APPROVED MAY 11 1977 *MS* 100 tablets 5 mg.
NDC 0007-3191-20

APPROVED MAY 11 1977 *MS* 100 tablets 5 mg.
NDC 0007-3191-20

AG. LOT EXPIRES

TRADE MARK STORE AT CONTROLLED ROOM TEMPERATURE

Each tablet contains amphetamine sulfate, 5 mg.
Usual Dosage: 5 to 10 mg., 3 times daily. See accompanying folder for complete prescribing information.
Important: Use safety closures when dispensing this product unless otherwise directed by physician or requested by purchaser.

Benzedrine
brand of
amphetamine sulfate
Tablets

Smith Kline & French Laboratories
Div. of SmithKline Corp., Phila., Pa. 19101

